KPIs & Operating Metrics(New)
Growth Metrics

Johnson & Johnson (JNJ) Total Current Liabilities (2009 - 2026)

Johnson & Johnson recorded quarterly Total Current Liabilities of $57.7 billion in Q1 2026, up 6.63% quarter-over-quarter from $54.1 billion in Q4 2025, and up 1.43% year-over-year from $56.9 billion in Q1 2025.

Johnson & Johnson's Total Current Liabilities history runs 18 years deep, the most recent figure standing at $57.7 billion for Q1 2026.

  • In Q1 2026, Total Current Liabilities rose 1.43% year-over-year to $57.7 billion; the TTM figure through Mar 2026 stood at $57.7 billion (up 1.43% YoY), while the FY2025 annual figure was $54.1 billion, up 7.56% from the prior year.
  • Total Current Liabilities came in at $57.7 billion for Q1 2026 at Johnson & Johnson, up from $54.1 billion in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $60.4 billion in Q2 2023 to a low of $43.4 billion in Q2 2022.
  • A 5-year average of $51.0 billion and a median of $51.3 billion in 2024 frame the typical range for Total Current Liabilities.
  • Across the five-year window, Total Current Liabilities soared 39.14% in 2023 and declined 19.29% in 2024, its largest moves.
  • Johnson & Johnson's Total Current Liabilities stood at $45.5 billion in 2022, then climbed by 1.62% to $46.3 billion in 2023, then grew by 8.73% to $50.3 billion in 2024, then advanced by 7.56% to $54.1 billion in 2025, then climbed by 6.63% to $57.7 billion in 2026.
  • According to Business Quant data, Total Current Liabilities over the past three periods registered $57.7 billion, $54.1 billion, and $50.9 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Current Liabilities (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn 36.63 Bn
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn 57.72 Bn
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn 42.10 Bn
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn 26.95 Bn
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn 24.96 Bn
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn 9.48 Bn
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn 34.35 Bn
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn 19.16 Bn
10 Gsk 88.34 Bn 83.66 Bn - 28.45 Bn

Historic Data

Download Data 🔒
DateValue
Mar 29, 2026 57.72 Bn
Dec 28, 2025 54.13 Bn
Sep 28, 2025 50.87 Bn
Jun 29, 2025 54.18 Bn
Mar 30, 2025 56.90 Bn
Dec 29, 2024 50.32 Bn
Sep 29, 2024 51.76 Bn
Jun 30, 2024 53.93 Bn
Mar 31, 2024 48.73 Bn
Dec 31, 2023 46.28 Bn
Oct 1, 2023 44.37 Bn
Jul 2, 2023 54.17 Bn
Apr 2, 2023 60.37 Bn
Jan 1, 2023 55.80 Bn
Oct 2, 2022 45.54 Bn
Jul 3, 2022 44.82 Bn
Apr 3, 2022 43.39 Bn
Jan 2, 2022 45.23 Bn
Oct 3, 2021 44.56 Bn
Jul 4, 2021 38.72 Bn
Apr 4, 2021 40.93 Bn
Jan 3, 2021 42.49 Bn
Sep 27, 2020 38.85 Bn
Jun 28, 2020 36.77 Bn
Mar 29, 2020 33.69 Bn
Dec 29, 2019 35.96 Bn
Sep 29, 2019 35.16 Bn
Jun 30, 2019 31.35 Bn
Mar 31, 2019 29.11 Bn
Dec 30, 2018 31.23 Bn
Sep 30, 2018 27.44 Bn
Jul 1, 2018 27.49 Bn
Apr 1, 2018 27.08 Bn
Dec 31, 2017 30.54 Bn
Oct 1, 2017 31.81 Bn
Jul 2, 2017 28.87 Bn
Apr 2, 2017 25.12 Bn
Jan 1, 2017 26.29 Bn
Oct 2, 2016 23.23 Bn
Jul 3, 2016 21.54 Bn
Apr 3, 2016 22.13 Bn
Jan 3, 2016 27.75 Bn
Sep 27, 2015 25.26 Bn
Jun 28, 2015 24.51 Bn
Mar 29, 2015 23.84 Bn
Dec 28, 2014 25.03 Bn
Sep 28, 2014 22.98 Bn
Jun 29, 2014 24.36 Bn
Mar 30, 2014 23.84 Bn
Dec 29, 2013 25.68 Bn
Sep 29, 2013 25.84 Bn
Jun 30, 2013 23.77 Bn
Mar 31, 2013 22.52 Bn
Dec 30, 2012 24.26 Bn
Sep 30, 2012 23.94 Bn
Jul 1, 2012 23.85 Bn
Apr 1, 2012 21.20 Bn
Jan 1, 2012 22.81 Bn
Oct 2, 2011 21.69 Bn
Jul 3, 2011 20.99 Bn
Apr 3, 2011 24.01 Bn
Jan 2, 2011 23.07 Bn
Oct 3, 2010 17.41 Bn
Jul 4, 2010 17.16 Bn
Apr 4, 2010 18.50 Bn
Jan 3, 2010 21.73 Bn
Sep 27, 2009 19.25 Bn
Jun 28, 2009 19.89 Bn